Kliničke studije za Лимфом u državi Masachuset
34 studija za Лимфом traži učesnike na lokacijama u državi Masachuset.
Gradovi u državi Masachuset
Zvanični tekst studije (na engleskom)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
Тражи се учесникФаза 1/2
6 Months – 17 Years · Оба пола · Ажурирано 13. 11. 2026. · NCT02332668A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06510361A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07015242A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Tufts Medical Center, Boston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07188558HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06487247A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
- Mass General Hospital, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07013435Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06475235GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07711483AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Boston
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06137144CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT03328078Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
Тражи се учесникФаза 3
Узраст од 18 до 18 · Оба пола · Ажурирано 6. 10. 2026. · NCT07509151A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT07192471Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
- Mass General Brigham, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07014293A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
Тражи се учесникФаза 1/2
До 25 година · Оба пола · Ажурирано 25. 9. 2026. · NCT04094610Epco, Zanu, Ritux for R/R FL or MZL
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06563596CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
12 Months – 21 Years · Оба пола · Ажурирано 11. 9. 2026. · NCT04870944Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 8. 2026. · NCT04104776Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT07426484DALY II USA/ MB-CART2019.1 for DLBCL
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT04792489A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 17. 6. 2026. · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 18. 5. 2026. · NCT01790152Remote Monitoring and Symptom Management Digital Application
- Massachusetts General Hospital, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 28. 4. 2026. · NCT07553572Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 21. 4. 2026. · NCT05646576Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
- Dana Farber Cancer Institute, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 13. 4. 2026. · NCT06923397A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424Odronextamab in Low Tumor Volume Advanced FL
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT07128641Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT06510309A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 3. 2026. · NCT05800366BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 20. 2. 2026. · NCT06854003CONFIRM: Magnetic Resonance Guided Radiation Therapy
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT04368702Avo In R/R And Previously Untreated MCL
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 1. 2026. · NCT04855695Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 12. 2025. · NCT07052695A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 12. 2025. · NCT06986174Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.